SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

吉西他滨 医学 内科学 危险系数 顺铂 胃肠病学 肿瘤科 化疗 胆道 胰腺癌 泌尿科 癌症 置信区间
作者
Rachna T. Shroff,Gentry Teng King,Sarah Colby,Aaron J. Scott,Mitesh J. Borad,Laura W. Goff,Khalid Matin,Amit Mahipal,Aparna Kalyan,Milind Javle,Imane El Dika,Benjamin Tan,P. Cheema,Anuj Patel,Renuka Iyer,Robin Kate Kelley,Jaykumar Thumar,Anthony B. El-Khoueiry,Katherine A. Guthrie,E. Gabriela Chiorean,Howard S. Höchster,Philip A. Philip
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:1
标识
DOI:10.1200/jco-24-01383
摘要

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
完美世界应助31313采纳,获得10
1秒前
共享精神应助weilu采纳,获得10
3秒前
4秒前
5秒前
卡皮巴拉下班完成签到,获得积分10
5秒前
6秒前
6秒前
大模型应助盛弟采纳,获得10
7秒前
7秒前
8秒前
现代代双发布了新的文献求助10
8秒前
8秒前
传奇3应助叮咚采纳,获得10
9秒前
桐桐应助Deadman采纳,获得10
9秒前
谢俏艳发布了新的文献求助10
10秒前
一只鱼发布了新的文献求助10
10秒前
XoXo完成签到,获得积分10
10秒前
dff发布了新的文献求助10
11秒前
刹那的颜色完成签到,获得积分10
13秒前
GEeZiii发布了新的文献求助10
14秒前
14秒前
31313发布了新的文献求助10
14秒前
科研助手6应助培爷采纳,获得10
15秒前
丽莉完成签到,获得积分10
16秒前
田様应助刘猛闯采纳,获得10
16秒前
16秒前
南星完成签到 ,获得积分10
17秒前
dff完成签到,获得积分10
17秒前
17秒前
zeng完成签到,获得积分10
18秒前
盛弟发布了新的文献求助10
19秒前
20秒前
22秒前
22秒前
22秒前
俞康伟发布了新的文献求助10
22秒前
嗯哼发布了新的文献求助10
23秒前
Rondab应助mariawang采纳,获得10
23秒前
在水一方应助难过的谷芹采纳,获得10
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021